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Abstract: At the end of 2005, an outbreak of fever
associated with joint pain occurred in La Re ´union. The
causal agent, chikungunya virus (CHIKV), has been known
for 50 years and could thus be readily identified. This
arbovirus is present worldwide, particularly in India, but
also in Europe, with new variants returning to Africa. In
humans, it causes a disease characterized by a typical
acute infection, sometimes followed by persistent arthral-
gia and myalgia lasting months or years. Investigations in
the La Re ´union cohort and studies in a macaque model of
chikungunya implicated monocytes-macrophages in viral
persistence. In this Review, we consider the relationship
between CHIKV and the immune response and discuss
predictive factors for chronic arthralgia and myalgia by
providing an overview of current knowledge on chikun-
gunya pathogenesis. Comparisons of data from animal
models of the acute and chronic phases of infection, and
data from clinical series, provide information about the
mechanisms of CHIKV infection–associated inflammation,
viral persistence in monocytes-macrophages, and their
link to chronic signs.
Introduction
The major epidemic of chikungunya virus fever (chikungunya)
that affected 266,000 people in La Re ´union in 2006 highlighted
the vulnerability of immunologically naive populations and raised
interest in this disease in the media, governments, and the scientific
community [1]. Over and above the number of cases, with one-
third of the population affected, this epidemic revealed new
features of chikungunya pathogenesis.
An adaptive mutation in the virus led to Aedes albopictus
becoming a major vector for chikungunya virus (CHIKV) [2],
resulting in a risk of disease in previously unaffected areas. In
addition, other new or previously underestimated features of the
virus have also come to light in recent chikungunya epidemics.
Atypical symptoms were observed in the La Re ´union epidemic
(Table 1), albeit in a small percentage of patients (,0.3% [3,4]).
However, more importantly, this epidemic highlighted the
persistence of chronic features in a significant proportion of
patients, as first reported in the early 1980s [5–9] but not
investigated further. These chronic signs of chikungunya are
disabling and merit further attention, because there is currently no
recommended treatment for chikungunya based on clinical trials
[10–13]. Treatment instead depends on the response of the
patient, ranging from non-steroidal anti-inflammatory drugs, to re-
education, to simple rest [14,15].
We aim here to present current knowledge on CHIKV infection
and related aspects, such as the inflammatory response which
potentially leads to the development of chronic syndromes.
Clinical Symptoms, from Acute to Chronic
Chikungunya
CHIKV spreads rapidly in the body after initial infection
(Figure 1). The clinical signs of acute infection are not entirely
specific and may vary between cohorts (Table 1). A small but
significant number of infected people present asymptomatic
infection (5% to 18% [16–18]), significantly more often below
25 years [19,20]. However, concomitant fever and arthralgia is a
common specific sign [17,20–22]. The La Re ´union epidemic
highlighted various ‘‘new’’ symptoms considered atypical and
frequently associated with severe forms, other than in very rare
cases of vertical transmission (Table 1) [23]. Most of these
symptoms were also observed in India and in travelers returning
from areas of endemic disease [7,24–26].
Acute-phase symptoms usually disappear after 2 weeks.
However, arthralgia and/or myalgia may persist for weeks,
months, or even years. Some patients go on to develop a genuine,
chronic arthritic syndrome. Typically, joint damage fluctuates over
time, but always affects the same parts of the body, mostly the
extremities (hands, ankles, knuckles; Table 2) [5,7,8,26,27].
Chronic chikungunya has been described before, but the La
Re ´union epidemic brought it to public attention. In 1979, Fourie
and Morrison described a rheumatoid arthritic syndrome affecting
18% of patients in South Africa [9]. Their observations were
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www.plosntds.org 1 March 2012 | Volume 6 | Issue 3 | e1446confirmed in 1983 by Brighton et al., who reported that 12% of
patients with CHIKV in South Africa continued to display
rheumatic manifestations years after the acute phase [6]. Being
over the age of 40 years was identified as a risk factor for
chronicity. This rheumatic syndrome may reflect the ability of
CHIKV to persist in some compartments by mechanisms that
remain poorly understood.
Following the 2005–2006 epidemic in La Re ´union, 36% of
patients reported the persistence of symptoms 15 months after
disease onset, and 21% reported at least one recurrence [8]. In this
group, age over 45 years, the pain intensity score ($7 on a 0–10
scale) during acute disease, and pre-existing osteoarthritis
conditions were associated with persistence. However, classifica-
tion was based on self-perceived recovery from rheumatic
manifestations of chikungunya, and it is therefore very difficult
to differentiate between osteoarthritis and chikungunya in these
patients (Table 2). Nevertheless, age and pain intensity score
remain robust predicting factors. Similar chronic forms of
chikungunya had previously been reported in other patient series
in La Re ´union by Borgherini et al. [5] and in travelers returning
from Indian Ocean islands by Simon et al. [7]. These late signs
may not be specific to the CHIKV strain of the 2005–2006
outbreak, as they were also reported for a closely related viral
strain in India, with various frequencies in the 10 months following
the acute phase: 16% in Maharashtara and 49% in Karnataka
[19,27] (Table 2). In Karnataka, Manimunda et al. examined 20
Table 1. Acute chikungunya symptoms in typical and atypical forms in adults, children, and newborns.
Setting
La Re ´union and Indian Ocean
Islands [3,4,14,21,22,67–69] India [16,19,27,70–76] Singapore [77] Malaysia [78,79]
Mean age (year) 34620 35 (median) 37(median) 35.9618
Sex ratio (male/female) 0.84 0.6 – 0.9 3.4 0.82 – 1.03
Typical form symptoms %
(common before 2006)
Fever 100 81 – 100 90 86 – 100
Arthralgia joint pain/swelling 100 86 – 80 88 82 – 100
Cephalalgia headache 70 93 43 30 – 50
Myalgia muscle pain 64 48 – 84 61 10 – 48
Rash 39 36 – 50 36 64 – 17 – 50
Erythema 33 —
Asthenia fatigue 67 43
Atypical Symptoms % (as
defined in La Re ´union; [3,4])
n=876; atypical form is 36% of severe acute chikungunya but less than 0.3% total cases in La Re ´union
Maculopapular eruption 33 17
Meningo-encephalitis 16 25
Diarrhea / vomiting 18 12/4 3/8
Renal failure 20 —
Respiratory failure 16 —
Myocarditis / pericarditis 6 11
Hepatitis 6 — Yes
a [80]
Sensory changes (muffling of
noise, sensitivity to light)
93 3
Aphtous-like ulcer — 21
Hyperpigmentation 15 20
Genital ulcers — 1
Optic neuritis ,1 ,11 1
b
Facial paralysis — 2
Guillain-Barre syndrome 1 Yes
a [81]
Atypical symptoms
in young children %
[3,23,82] [72,75]
Hyperalgia high grade pain 27 Yes
a
Diarrhea/vomiting 27 Yes
a
Convulsions 22 Yes
a
Bullous dermatosis 17 Yes
a
Purpura 8 Yes
a
Encephalitis 6 Yes
a
aAtypical forms were noticed but their prevalence was not evaluated.
bRetro-orbital pain.
doi:10.1371/journal.pntd.0001446.t001
www.plosntds.org 2 March 2012 | Volume 6 | Issue 3 | e1446of 94 patients with persistent joint pain by X-ray and MRI: 15% of
patients presented chronic inflammatory erosive arthritis after
CHIKV infection [27]. By contrast, Chopra et al. mostly reported
chronic pain, with rare cases of inflammatory arthritis, in a
population cohort study; these findings conflict with their previous
report on patients hospitalized at a rheumatology referral center
[19,28].
Persistent symptoms, including arthralgia, myalgia, and arthritis
(consistently found on radiological/MRI examination in various
sets of patients, see Table 2 and [7,26–29]) suggest the persistence
of virus in target organs or the establishment of a self-sustained,
deleterious mechanism leading to tissue damage, probably
inflammatory in nature. Very little is currently known about the
mechanism underlying chikungunya persistence. Studies in animal
models and clinical investigations are needed to address this point.
Animal Models
The mouse was the first organism used for in vivo studies of
CHIKV infection [30], but muscle and joint disease was achieved
only recently in this species [31–33]. Subcutaneous CHIKV
inoculation close to distal leg joints in adult C57Bl6 mice leads to a
muscle and joint disease, including loss of balance, hind limb
dragging, and skin lesions [31,32,34]. This strongly suggests that
the initial dissemination of CHIKV (Figure 1) is critical to the
setting of chikungunya. In this model, and using both Asian and
La Re ´union strains of CHIKV, Gardner and Morrison demon-
strated arthritis, tenosynovitis, and myositis, together with local
virus persistence in tissues after the phase of active replication in
the blood. Infiltration with monocytes and macrophages is also
observed in connective tissues, and subcutaneous peritendinous
tissues and muscle, on histological analysis and immunohisto-
chemistry with the F4/80 monoclonal antibody [31,33,34]. In
2006, we developed a model of macaque infection and virus
spread (Figure 1). This model was required for the rapid
implementation of preclinical trials following the La Re ´union
epidemic and the risk of extension to the Indian Ocean zone. We
infected cynomolgus macaques (Macaca fascicularis) with CHIKV
strain LR-2006-OPY1 from La Re ´union [29]. RT-PCR on
plasma revealed viral replication kinetics similar to those in
humans, together with profound leukopenia consistent with
lymphocyte and monocyte recruitment to tissues. Several soluble
factors, such as IFNa, IL-6, MCP1/CCL-2, and TNFa, were
found to be induced, to various levels, in a multiplex immunoassay
Figure 1. Virus dissemination and target organs. Following inoculation with CHIKV through a mosquito bite, the virus directly enters the
subcutaneous capillaries, with some viruses infecting susceptible cells in the skin, such as macrophages or fibroblasts and endothelial cells. Local viral
replication seems to be minor and limited in time, with the locally produced virus probably being transported to secondary lymphoid organs close to
the site of inoculation. The blood carries most viruses, as free virions or in the form of infected monocytes, to the target organs, the liver, muscle,
joints, and remote lymphoid organs. In these tissues, infection is associated with a marked infiltration of mononuclear cells, including macrophages,
particularly when viral replication occurs. The pathological events associated with tissue infection are mostly subclinical in the liver (hepatocyte
apoptosis) and lymphoid organs (adenopathy), whereas mononuclear cell infiltration and viral replication in the muscles and joints are associated
with very strong pain, with some of the patients presenting arthritis. * Guillain-Barre ´ syndrome and encephalitis are very rare events. { True arthritis
remains a rare event (from 2% to 10%); see Table 2.
doi:10.1371/journal.pntd.0001446.g001
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response, which renders viral replication undetectable, from 10
days after infection [35]. However, CHIKV persists in target
tissues after its clearance from the blood, as demonstrated by viral
RNA detection in an in situ hybridization assay using a CHIKV
subgenomic mRNA specific probe. Joints, secondary lymphoid
organs and, to a lesser extent, muscles, are affected. CHIKV
replicates in several cell types during the acute phase [35], but is
thereafter detectable only in macrophages, by immunohistochem-
ical analysis with a monoclonal antibody against the viral E2
glycoprotein. We detected infected monocytes-macrophages in the
blood 6 hours after infection (flow cytometry) [36] and in most
tissues on the following day (in situ hybridization, immunohisto-
chemistry, RT-PCR, and virus isolation). Significant macrophage
infiltration was also detected by histological analysis [35],
throughout the study and long after viral clearance from blood.
This monocyte-macrophage tropism is consistent with recent
findings from Lisa Ng’s team that human monocytes are
susceptible to infection in vitro, as shown by flow cytometry with
a monoclonal antibody against the E1 glycoprotein of CHIKV.
Infected monocytes generate new viruses, which can be detected
with HEK293 cells and titration assays, albeit at low levels [37].
Similarly, CHIKV can infect primary macrophages in vitro [38,39],
resulting in the production of highly variable amounts of virus,
from 10
3 to 10
6 pfu per ml [31,35,39,40]. These results are
consistent with human studies reporting that macrophages are
susceptible to CHIKV infection both in vivo and in vitro [41–43].
The alleviation of chikungunya-associated arthritis and myositis by
treatment with the MCP-1/CCL-2 inhibitor Bindarit in mice [33]
also strongly suggests that monocytes-macrophages, the main
targets in MCP-1/CCL-2 tissue tropism, are central to muscle and
joint disease.
There is currently no animal model reproducing the chronic
rheumatoid syndrome of chikungunya. Indeed, the disease has too
short a course in mice [31,32], and no joint damage was evident in
macaques [35], in which only virus persistence in joints, long after
the acute phase, could be demonstrated. Nevertheless, both
models suggest that inflammation, macrophage tissue tropism, and
local viral persistence are involved in the establishment of chronic
disease.
Viral Persistence and Clinical Expression
Recent data have clearly implicated inflammatory mediators
not only in the acute and resolution phases of chikungunya, but
also in the establishment of chronic disease. Figure 2 shows how
CHIKV infection may lead to chronic joint damage.
The Acute Phase
The first phase of CHIKV infection is typical of acute viral
infection, with a very early type 1 interferon (IFN) response
[41,44–46]. IFN-a is detected on the first day of infection and its
concentration is correlated with plasma viral load, which is
significantly higher in elderly patients [47]. However, plasma
Table 2. Chronic chikungunya symptoms.
Setting (Date Referred)
La Re ´union (2005
to 04/2006) [5]
La Re ´union (04/
2006–2007) [41,83]
India Karmataka
(2008) [27]
India Maharashtra
(2006) [19]
Singapore
(2008) [44,77]
Number of chronic cases /
number of patients in the
cohort (month after acute phase)
56
a/88 (.18) 116/133 (12) 94/203 (.9) 59/315 (12) 14
b/97 (3)
Mean age of chronic cases 60 58 (median) 41 48 3866
Sex ratio (M/F in chronic) 0.93
c 0.33 0.81 0.33* 1.8
Hospitalized (%) 65.9 85 0 0 100
Joint pain (%) 100 100 94 100 100
Fatigue (%) NR NR 27 NR NR
Joint swelling/tenosynovitis (%) 16 NR 58.5 NR NR
Localization NR
Symmetrical (%) 64 More often 83 NR
Knee (self/exam) (%) 21 (57) 20 59.5 57
Ankles/wrist (%) 29/16 31/21 54/31 15/59
Shoulder (%) 30 NR 15 52.5
Hips (%) 5N R1 1 7
Continuous pain (%) 55 68 NR 100
Rheumatoid like polyarthritis (%) ND 10 36
d 100 NSA 0
Spondylo-arthropathy (%) ND 22 IE 7 IA 0
Underlying disease (%) 71 Not detailed 10/20 tested by MRI NR 0
Previous arthritis/arthralgia (%) 5 1 77 50
*p,0.01 Khi-2 between infected time 0 and chronic at 12 months (calculated by us).
aLow ALT/ASAT level related to persistence (p,0.01) like platelet count.
bLower level of creatinine p=0.036.
cNo difference chronic versus recovered.
dAmerican College of Rheumatology criteria for rheumatoid arthritis in [28]; note that tenosynovitis is prominent (as seen by Hoarau et al. [41]).
IA, inflammatory arthritis; IE, inflammatory, erosive; MRI, magnetic resonance imaging; ND, not detected or prevalence not evaluated; NR, not reported; NSA, non-
specific arthritis.
doi:10.1371/journal.pntd.0001446.t002
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46,48], despite the observation by Hoarau et al. that IFN-c and
IL-12 levels were high in patients from La Re ´union [41].
Wauquier et al. also reported IFN-c overproduction, together
with IFN-a2, during the acute phase [45], in Gabon. Chow et al.
showed, in Singapore, that IFN-a was produced for 10 days before
viral clearance from plasma, but they detected no IFN-c in serum
[44]. The acute IFN response may be short-lived, as it has not
been detected directly in studies otherwise reporting an early
increase in levels of the IFN-inducible chemokines MIG/CXCL-9
and IP-10/CXCL-10) [46,48].
Viral load is related to the concentrations of IFN-a, IL-1-RA,
IL-6, MCP-1/CCL-2, IL-12 and IP-10/CXCL-10 [44], IL-18,
and IL-18BP [49]. The inflammatory response to CHIKV
infection therefore clearly contributes to virus elimination.
Unfortunately, none of the population studies [19,27,41,44–
46,48] carried out assessed joint or muscle pain, so it is not
currently possible to determine the relationship between viral load
or inflammatory mediators and symptoms. Wauquier et al.
reported markedly higher levels of proinflammatory mediators
than other teams [41,44–46,48]. This difference may reflect
regional characteristics of the cohorts studied (Gabon versus Italy,
La Re ´union, India, and Singapore), with different genetic
backgrounds and heterogeneous sanitary conditions, but it may
also reflect sampling schedule. For example, IL-6 concentration
depends largely on sampling time, as observed in our macaque
model [35]. Similarly, IL-12 concentration was high in the Gabon,
La Re ´union, and Singapore series [41,44,45], but was lower than
that in uninfected controls in Italy, although these results may not
be directly comparable due to the use of different technologies
[46]. During the experimental infection of macaques with
CHIKV, we observed an early induction of IFN-a, MCP-1/
CCL-2, and IL-6, followed by the detection of MIP-1a/CCL-3
and MIP-1b/CCL-4, IFN-c, and TNF-a. These last two effectors
remain at higher concentrations than in controls until the end of
the recovery phase (15–20 days post infection) [35]. In the mouse
Figure 2. Mechanisms of CHIKV persistence and tissue inflammation in patients with chronic disease. (1) Months after the acute
infection, monocytes, T cells, and natural killer (NK) cells are still attracted to the inflamed joint, where they become activated. (2) The infectiono f
macrophages in joints is associated with local inflammation and the production of cytokines, chemokines, and pro-inflammatory effectors, such as
MCP-1/CCL-2, IL-8, IL-6, IFN-a, and MMP2. (3) The phagocytosis of apoptotic bodies from infected cells probably contributes to viral persistence.
Nevertheless, the beneficial or deleterious effect of local inflammation on viral persistence remains unclear. (4) When it occurs, arthritis is
accompanied by high rates of fibroblast apoptosis and cartilage destruction. Chronic inflammation probably plays a major role in this damage and
associated pain. (5) The potential relationship between local inflammation of the joint and a state of systemic activation, as demonstrated by the
presence of inflammation markers in plasma and blood cells, remains unclear.
doi:10.1371/journal.pntd.0001446.g002
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chronology, but with differences in plasma cytokine concentra-
tions, including higher levels of TNF-a [31].
The Chronic Phase and Its Predictive Factors
The inflammatory response to CHIKV infection leads to viral
elimination from the blood and clinical recovery. However, it is
now clear that disease may persist in a subgroup of patients
presenting variable levels of myalgia and arthralgia, culminating in
some cases in a debilitating arthritic syndrome. Five studies have
tried to identify the factors associated with chronic chikungunya
disease in groups of patients in Singapore [44], La Re ´union [41],
Dakshina Kannada (India) [27,48], and Emilia Romagna (Italy)
[46] (Table 3), with times measured from inclusion (i.e., first
consultation).
The proportion of patients with chronic signs attributable to
CHIKV differed between series. In Singapore, 13% of the
infected patients still had chronic arthralgia 3 months after
infection [44]. In Emilia Romagna,70% of patients had
symptoms persisting at 6 months and 32% had symptoms
persisting at 12 months after inclusion [46]. Similarly, 49% of
patients in the 2008 outbreak in Dakshina Kannada still had
symptoms attributable to chikungunya 10 months after inclusion
[27], and almost half the studied patients from La Re ´union had
persistent symptoms, possibly including arthritis, 1 year after
inclusion [41].
Table 3. Biological parameters associated with disease chronicity in chikungunya patients.
Parameter Recovered Patients Chronic Patients a Risk Series
Age 50.3613.7 70.7615.5 2% La Re ´union [41]
40.2612.3 31.565.2 NS Singapore [44]
34.5 41.5 NS Dakshina Kannada [48]
Cure rate 10 months after inclusion declining with age ,1% Dakshina Kannada [27]
Acute phase
Viral load at inclusion 2.3610
663.7610
6 cp/ml 3.9610
966.9610
9 cp/ml 5% La Re ´union [41]
6.9610
761.5610
8 pfu/ml 1.12610
465.2610
3 pfu/ml NS Singapore [44]
Plasma CRP concentration
at inclusion
11.33610.05 mg/ml 60.2659.7 mg/ml 7% La Re ´union [41]
Circulating cytokine
concentrations at inclusion
Th1 and Th2, moderate Trend toward a Th1 bias NS La Re ´union [41]
Recovery phase
Circulating GM-CSF, 2–3
months post inclusion
Normal Higher than controls ,5% Singapore [44]
Circulating eotaxin and
HGF, 2–3 months post inclusion
Higher than controls Normal ,5% Singapore [44]
Circulating IL-6, 2–3
months post inclusion
Lower than controls Normal ,5% Singapore [44]
Chronic phase
Circulating IL-12
p40 post acute phase
Not detectable Persistent (61 ng/ml) 0.5%
a La Re ´union [41]
Circulating MIG/CXCL-9
and IP-10/CXCL-10, 6
months post inclusion
Higher in patients with chronic disease than in fully recovered patients ,5% Emilia Romagna [46]
CHIKV-specific IgG titer,
6 months post inclusion
Higher in patients with chronic disease than in fully recovered patients ,5% Emilia Romagna [46]
Circulating cytokines,
10–12 months post inclusion
Th2 (increased IL-5) Th1: IL-1b, IL-1RA, IL-6, MCP-1/CCL-2,
MIP-1a/CCL-3, MIP-1b/CCL-4
,5% Dakshina Kannada [48]
No difference between patients with chronic disease and fully recovered patients NS Emilia Romagna [46]
IFN-a mRNA in PBMC,
12 months post inclusion
Not detectable High levels 2%
a La Re ´union [41]
Joint tissue
CHIKV detection in the
joint at late time points
(.12 months)
No Yes, in macrophages NA La Re ´union [41]
Joint inflammation at late
time points (.12 months)
No MCP-1/CCL-2, IL-8, IL-6, MMP2, IFN-a NA La Re ´union [41]
aMann and Whitney test performed by us.
Inclusion: first presentation of the patient during acute disease.
Numbers (and sex ratios) of patients with chronic disease were 5 (4) in Singapore, 32 (0.15) in La Re ´union, 94 (0.82) in Dakshina Kannada, and 35 (sex ratio not available)
in Emilia Romagna.
cp, viral RNA copies; CRP, C reactive protein; NA, not applicable; NS, not significant; pfu, plaque-forming units.
doi:10.1371/journal.pntd.0001446.t003
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infection characteristics. Hoarau et al. reported high baseline viral
loads in patients with chronic disease (10 versus 2.1610
9 copies/
ml, p=0.005), whereas the opposite trend was reported in
Singapore. Viral load was not considered in the Emilia Romagna
and Dakshina Kannada series.
Patient age appeared to be crucial in the La Re ´union and
Dakshina Kannada groups, but not in Singapore (see Table 3).
Patients with chronic chikungunya were older than those who
recovered fully in La Re ´union [41], whereas cure rate at 10
months decreased with age in Dakshina Kannada [27].
Hoarau et al. also suggested a link between chronic disease and
a stronger inflammatory Th1 response to acute infection (Table 3).
Patients with chronic disease displayed stronger systemic inflam-
mation during the acute phase (higher CRP levels, p=0.07),
potentially associated with higher levels of TNF-a, IL-8, IL-6, and
IL-12, although these differences were not significant [41].
Conversely, the Th2 cytokines IL-4 and IL-13 tended to be
produced in smaller amounts during the acute phase in patients
progressing to chronic disease.
The recovery period lies between the acute and chronic phases.
During this period, active regulatory mechanisms responsible for
the resolution of inflammation take place. These mechanisms
mostly involve macrophages and their unique ability to arouse and
regulate inflammation (Figure 3). Chow et al. distinguished early (4
days after inclusion) and late (10 days after inclusion) convalescent
phases, whereas Hoarau et al. measured cytokine levels 15 days
after inclusion, corresponding roughly to the late convalescent
phase. Chow et al. reported the upregulation of both pro-
inflammatory and regulatory mediators (IL-2R, IL-4, MIG/
CXCL-9, MIP-1a/CCL-3, hepatocyte growth factor [HGF],
basic fibroblast growth factor [bFGF], granulocyte colony-
stimulating factor [G-CSF], and eotaxin/CCL-11) during the
early phase of convalescence. During the late convalescent phase,
epidermal growth factor [EGF] and RANTES/CCL-5 concen-
trations peaked in patients from Singapore and IFN-c and IL-12
were overproduced in patients from La Re ´union.
The recovery phase appears to play a critical role in the
establishment of chronic disease, at least in patients from
Singapore. Chow et al. found higher GM-CSF (granulocyte-
macrophage colony-stimulating factor) concentrations in patients
subsequently displaying chronic symptoms than in those who fully
recovered and the control group [44]. This is consistent with the
role of GM-CSF as a proinflammatory mediator in rheumatoid
arthritis [50,51] and in the activation of monocytes-macrophages
[52]. Conversely, during convalescence, cured patients continued
to have significantly higher levels of HGF and eotaxin/CCL-11
than control subjects and patients with chronic pain syndrome.
Eotaxin is a Th2 chemokine and natural antagonist of CCR-2, the
receptor for MCP-1/CCL-2 [53], whereas HGF inhibits the
production of MCP-1/CCL-2 in response to TNF-a in vitro [54].
The concomitant overproduction of eotaxin and HGH therefore
probably reflects the inhibition of MCP-1/CCL-2 signaling via
CCR-2. MCP-1/CCL-2 is a major chemoattractant for mono-
cytes-macrophages. It is strongly expressed during acute infection
in humans and in animal models [31,35,46,48,55,56]. It is the
target of the pharmacological inhibitor Bindarit, a molecule that
alleviates chikungunya arthritis and myositis in the mouse model
[33]. During recovery, plasma MCP-1/CCL-2 concentration
decreases, remaining slightly (and non-significantly) above normal
levels 2–3 months later. The high levels of eotaxin and HGF
production in patients attaining full remission [44], and the
beneficial effects of CCR-2 inhibition in the mouse model [33],
strongly suggest that recovery requires the inhibition of signaling
Figure 3. The macrophage is central to chronic signs of chikungunya disease. Macrophage infiltration, under the control of MCP-1/CCL-2, is
a critical feature of damaged tissues. The inflammatory effectors IL-6, IL-8, MCP-1/CCL-2, MMP2, and INF-a are specifically expressed in the tissues of
patients with chronic chikungunya, who have high IFN-a and IL-12 mRNA levels in their circulating leukocytes. This classical inflammatory process
may be regulated by HGF and eotaxin, which have different expression profiles during the recovery phase in patients with chikungunya, depending
on whether or not these patients go on to develop chronic disease. HGF also promotes muscle regeneration. Once they have infiltrated the joint or
muscle, the macrophages are activated and regulate the local Th1/Th2 balance as a function of their own activation status (classical/M1 or
alternative/M2). GM-CSF and HGF, which have M1 and M2 effector activities, respectively, may modulate this balance as they are differentially
expressed in acute and chronic chikungunya. CHIKV persists in infected macrophages only in patients with a chronic rheumatic syndrome. The
reciprocal influences connecting viral persistence and local inflammation are not known. Solid arrows: activation. Solid stopped lines: regulation.
Dotted arrows: expression.
doi:10.1371/journal.pntd.0001446.g003
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recruitment to tissues (Figures 2 and 3).
HGF also has beneficial effects on muscle regeneration [57]. It
regulates the IL-6/IL-10 balance in favor of IL-10 in various
models [54,58,59], probably by inhibiting NFkB [60]. HGF
overproduction may therefore account for the low IL-6 concen-
trations in patients fully recovering in Singapore and the small
number of severe cases in this group. A Th2-type response in
patients that recovered (10 months after inclusion) was also
described by Chaaithanya et al. [48]. Conversely, a deficit of HGF
may account for the persistence of high IL-6 levels in the chronic
phase, both systemically [19,48] and locally [41]. IL-6 is involved
in joint pain [61] and rheumatoid arthritis [62], and it increases
the production of cartilage-destroying enzymes [63].
In addition to IL-6, chronic chikungunya (.6 months) is also
associated with other systemic markers of inflammation, such as
IFN-a [41], the IFN-inducible chemokines MIG/CXCL-9 and
IP-10/CXCL-10 [46], and the cytokines IL-1b, IL-1RA, IL-6,
CCL-2/MCP-1, CCL-3/MIP-1a, CCL-4/MIP-1b [48], IL-12
[41], and IL-17 [44]. Th1-type activation has also been observed
in altered joint tissues, in which it is associated with viral
persistence in macrophages [41] (Figure 2).
Thesedatahighlighttheroleofmacrophagesinchronicarthralgia
and arthritis as a virus reservoir and as the main local cell type
involved in regulating inflammation and Th1/Th2 balance. The
central role of macrophages in chronic chikungunya disease and
various pathogenic pathways involved are illustrated in Figure 3.
Conclusion
Regulatory mechanisms seem to be required to prevent the
establishment of chronic disease weeks or even months after viral
clearance from the blood. The absence of such mechanisms leads to
chronic arthralgia, or the arthritis observed in the group from La
Re ´union. Hoarau et al. detected CHIKV and various markers of
inflammation(IFN-a, IL-6, MCP-1/CCL-2, IL-8, and MMP2) in the
synovium of a patient suffering from chronic pain, but not in
synovium of two patients who recovered fully [41]. The persistence of
a local reservoir of CHIKV in joints may therefore be characteristic
of chronic disease (see Figures 2 and 3). This persistence is consistent
with findings in the macaque model, in which CHIKV is detected
after up to 90 days in tissues, including joint tissues [35].
The persistence of CHIKV in joints may therefore lead to
chronic local inflammation, causing pain. Local inflammation
would in turn establish local conditions favoring CHIKV
persistence. Indeed, we know from HIV/AIDS studies [64,65] that
inflammation contributes to the destruction and elimination of
viruses, but may also maintain the levels of activation required for
sustained replication and viral persistence in tissues, particularly in
macrophages, a cell target common to HIV and CHIKV. Thus,
CHIKV persistence may therefore also result from an imperfectly
resolved inflammatory phase, through the ingestion of apoptotic
cells by macrophages and skewed activation, for example [42,66].
Hoarau et al. reported high plasma concentrations of IL-12 and
IFN-a mRNA in blood mononuclear cells after the convalescence
phase, in patients with chronic disease, between 6 months and 1
year after infection. In the patients from Singapore, the
concentrations of these two cytokines, measured by alternative
techniques, peaked in the acute phase and returned to normal
levels at 2–3 months, even in patients who still had clinical
symptoms. Consistent with the findings of Hoarau et al., Kelvin et
al. and Chaaithanya et al. reported high levels of Th1-type
cytokines in the blood of patients with chronic disease (see Table 3).
It would thus be extremely interesting to obtain data for larger
groups of patients, to determine precisely the cytokine profiles
associated with chronic disease. These profiles would constitute a
powerful prognostic tool, facilitating preventive treatment and
relevant targeted immunomodulatory treatment. Thus, despite
certain discrepancies, the available studies analyzed here suggest
that chronic disease requires a defect in the regulation of
inflammation during the acute and convalescence phases. This
lack of regulation results in a deleterious inflammatory process that
persists for at least 1 year after the first clinical signs.
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